BTIG raised the firm’s price target on Theravance Biopharma (TBPH) to $40 from $25 and keeps a Buy rating on the shares. The firm is revisiting its annualized net price for ampreloxetine in nOH and lowering standalone operating expense assumptions to better reflect a rare disease launch, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma management to meet virtually with BTIG
- Theravance Biopharma’s Earnings Call Highlights Robust Growth
- Theravance Biopharma price target raised to $20 from $15 at H.C. Wainwright
- Theravance Biopharma: Hold Rating Amid Steady Growth and Pipeline Uncertainty
- Theravance Biopharma Reports Strong Q3 2025 Results